EC20

DRUG4 trials

Sponsors

Endocyte

Conditions

CancerNon Small Cell Lung CancerOvarian Cancer

Phase 1

Study of EC0489 for the Treatment of Refractory or Metastatic Tumors

CompletedNCT00852189

Start: 2009-04-30End: 2012-04-30Updated: 2012-08-08

Phase 2

Platinum Resistant Ovarian Cancer Evaluation of Doxil and Vintafolide (MK-8109, EC145) Combination Therapy (8109-009, EC-FV-04)

CompletedNCT00722592

EndocyteOvarian Cancer

Start: 2008-09-30End: 2012-12-31Updated: 2015-01-07

Phase 2 Study of EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone in Participants With FR(++) 2nd Line Non Small Cell Lung Cancer

CompletedNCT01577654

EndocyteNon Small Cell Lung Cancer

Start: 2011-03-31End: 2015-08-31Updated: 2021-04-01

Phase 3

Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)

TerminatedNCT01170650

EndocyteOvarian Cancer

Start: 2011-04-22End: 2015-09-08Updated: 2021-09-30

Related Papers

Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) at 50 mg/m<sup>2</sup> versus 40 mg/m<sup>2</sup> in patients with platinum-refractory and -resistant ovarian carcinoma: the JGOG 3018 Trial

Journal of Gynecologic Oncology2020-11-127 citations

Radiation dosimetry of 18F-AzaFol: A first in-human use of a folate receptor PET tracer

EJNMMI Research2020-04-0839 citations